Clinical Trial Update: TCR-engineered T Cells in Solid Tumors: IMA202-101 [Phase 1]

View source ↗

Summary

This report updates the completion of a Phase 1 trial of IMA202-101, a TCR-engineered T cell therapy, tested in adults with solid tumors. It notes completed sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumor

Drugs mentioned

• IMA202-101

Snippet

Sponsor: Immatics US, Inc. | Conditions: Solid Tumor, Adult, Refractory Cancer | Phase 1 | Status: COMPLETED